About BSPAR

 

BSPAR is a Charitable Company registered in England and Wales with objectives to:

  • Encourage and support clinical care, research education and training in paediatric rheumatology in the U.K.

  • Work with the Royal College of Paediatrics and Child Health (RCPCH) and the British Society of Rheumatology (BSR) in their efforts on behalf of paediatric rheumatology and to advise the RCPCH when so requested.

  • Work with other professional groups or interested parties.

 

 

BSPAR's aims in meeting these objectives

  • To improve the provision and quality of healthcare for patients with rheumatic disease in childhood and adolescence, by encouraging and supporting clinical care, research, education and training in paediatric rheumatology in the U.K.  BSPAR works with the RCPCH, BSR and other professional groups or interested parties to further our charitable aims. 

  • Through the relevant sub-committees of the executive committee, BSPAR advises locally and nationally on policy relating to training in paediatric rheumatology - for doctors, nurses, physiotherapists, occupational therapists, and other allied health professionals who work with children and adolescents with rheumatic diseases.  We also consult with other groups such as ARMA, on Standards of Care for our patients, provide input to NICE on relevant drugs and comment on clinical issues of relevance to our patient base.

  • Throughout our activities it is our patients and their families who benefit directly from the improved training and dissemination of information that BSPAR provides to the medical and allied health carers with whom they come into direct contact.  By education and training, all healthcare professionals improve the service which they provide to their patients.

  • As part of our commitment to the safe and effective administration of drugs to our patients, BSPAR works in collaboration with Pfizer, the manufacturer of the first anti-TNF drug therapy approved by NICE for use in juvenile idiopathic arthritis (Etanercept), to run a pharmacovigilance registry of patients treated with this agent, in an effort to obtain long-term effectiveness and safety of this form of treatment.

  • In its activities, BSPAR provides information to patients and their families/carers, available on its website (www.BSPAR.org.uk).  Similarly, information for healthcare professionals is available to non-members as well.  The AGM education meeting is open to all healthcare professionals, but members enjoy a reduced fee for this meeting.